Sun Pharma Q1FY27 profit rises 27% as India formulations grow 16%
Sun Pharma reported Q1FY27 net profit of Rs 2,894.79 crore, up 27% year on year, while revenue rose 10.46% to Rs 15,299.88 crore. India formulations sales grew 16% to Rs 5,475 crore, lifting domestic market share to 8.5%.
Sun Pharma reported 27% YoY Q1FY27 profit growth as India formulations rose 16% to Rs 5,475 crore. Its domestic market share reached 8.5%, supported by five product launches. The Organon acquisition remains on track for early-2027 completion.
Why this matters
No related recent signals were provided. Sun Pharma's Q1FY27 results establish a stronger domestic growth marker, with India formulations outpacing overall revenue growth and supporting market-share gains.
Retail-company signals are accelerating, up 258580% QoQ.